Demonstrating the multidisciplinary nature of the congress, an oncologist, a radiotherapist, and a urologist each received a Best Poster Award – Prostate Cancer at the 13th European Multidisciplinary Congress on Urological Cancers (EMUC21) in Athens.
Oncologist Dr. Simon Spohn (DE, see photo above) received the award for his team’s study “PSMA PET- and mpMRI-guided focal radiation dose escalation in primary prostate cancer patients – a planned safety analysis of a two-armed prospective phase-2 trial (HypoFocal).”
“Combined PSMA PET and mpMRI-based ITM definition results in significantly larger boost volumes. Despite these large boost volumes, the focal dose escalation was feasible for both arms, showing acceptable acute GU and GI toxicities without compromising QoL,” the conclusion of the study read. “Radiation proctitis demands careful management.”
Dr. Spohn added, “We will further evaluate this approach in a phase-3 trial, in which we will compare moderately hypofractionated radiotherapy with focal-dose escalated SBRT and intervening PSMA PET.”
Dr. Constantinos Zamboglou (DE, right) receives the award for Best Poster – Prostate Cancer
MFS after sRT in the PSMA PET era
Radiotherapist Dr. Constantinos Zamboglou (DE), who was also part of Dr. Spohn’s team, was bestowed the award for the “Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicentre analysis” study (see Photo 2). In this multicentre study, PSMA PET/CT was used to guide salvage radiotherapy (sRT) in all patients.
“The strong prognostic impact of PSA serum values prior to sRT on metastasis-free survival (MFS) is confirmed,” Dr. Zamboglou said. “Additionally, the presence of PET-detected pelvic lymph nodes is proposed as a new biomarker associated with MFS after sRT in the PSMA PET era.”
Prof. Arnulf Stenzl (DE, right) accepts the award for Best Poster – Prostate Cancer
mCRPC-patient pain burden
Finally, Prof. Arnulf Stenzl (DE) accepted the award for the “Patient-reported pain by baseline pain status in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1” study (see Photo 3).
“Don’t look at me, but look at the authors. There are many of those that have probably contributed more than I did. This is definitely a study we are proud of,” Prof. Stenzl said before receiving the award.
About the study, he said, “Among patients with moderate or severe pain at baseline, treatment with talazoparib was associated with an improved pain burden, except for the pain interference in the non-BRCA1/2 subset. No changes in the pain burden were observed among patients with asymptomatic or mild pain at baseline.”
Read the award-winning posters in the EMUC21 Resource Centre! EMUC21 delegates can access all scientific content here. All presentations, full-text abstracts, and (e-)posters are easily accessible here throughout the congress.
